Annual Operating Expenses
$1.80 B
+$53.19 M+3.05%
December 31, 2024
Summary
- As of February 24, 2025, BMRN annual total operating expenses is $1.80 billion, with the most recent change of +$53.19 million (+3.05%) on December 31, 2024.
- During the last 3 years, BMRN annual operating expenses has risen by +$349.37 million (+24.09%).
- BMRN annual operating expenses is now at all-time high.
Performance
BMRN Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$449.77 M
+$6.36 M+1.43%
December 31, 2024
Summary
- As of February 24, 2025, BMRN quarterly total operating expenses is $449.77 million, with the most recent change of +$6.36 million (+1.43%) on December 31, 2024.
- Over the past year, BMRN quarterly operating expenses has increased by +$6.36 million (+1.43%).
- BMRN quarterly operating expenses is now -14.47% below its all-time high of $525.88 million, reached on December 31, 2023.
Performance
BMRN Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
BMRN Operating Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +3.0% | +1.4% |
3 y3 years | +24.1% | +12.8% |
5 y5 years | +24.1% | +12.8% |
BMRN Operating Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +24.1% | -14.5% | +21.4% |
5 y | 5-year | at high | +26.0% | -14.5% | +32.9% |
alltime | all time | at high | >+9999.0% | -14.5% | >+9999.0% |
BioMarin Pharmaceutical Operating Expenses History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $1.80 B(+3.0%) | $449.77 M(+1.4%) |
Sep 2024 | - | $443.41 M(-3.8%) |
Jun 2024 | - | $461.12 M(+3.6%) |
Mar 2024 | - | $445.19 M(-15.3%) |
Dec 2023 | $1.75 B(+11.5%) | $525.88 M(+38.5%) |
Sep 2023 | - | $379.60 M(-4.9%) |
Jun 2023 | - | $399.09 M(+0.1%) |
Mar 2023 | - | $398.54 M(-8.2%) |
Dec 2022 | $1.57 B(+8.0%) | $434.15 M(+11.2%) |
Sep 2022 | - | $390.53 M(+5.4%) |
Jun 2022 | - | $370.62 M(-0.1%) |
Mar 2022 | - | $371.07 M(-5.9%) |
Dec 2021 | $1.45 B(+1.5%) | $394.29 M(+10.6%) |
Sep 2021 | - | $356.57 M(-1.2%) |
Jun 2021 | - | $360.81 M(+6.6%) |
Mar 2021 | - | $338.43 M(-8.0%) |
Dec 2020 | $1.43 B(-1.5%) | $367.77 M(+7.5%) |
Sep 2020 | - | $342.05 M(-8.2%) |
Jun 2020 | - | $372.45 M(+7.9%) |
Mar 2020 | - | $345.26 M(-3.3%) |
Dec 2019 | $1.45 B(+8.9%) | $357.07 M(-0.9%) |
Sep 2019 | - | $360.14 M(-1.8%) |
Jun 2019 | - | $366.63 M(+0.3%) |
Mar 2019 | - | $365.51 M(+11.5%) |
Dec 2018 | $1.33 B(+9.9%) | $327.90 M(-0.2%) |
Sep 2018 | - | $328.55 M(-3.1%) |
Jun 2018 | - | $339.09 M(+1.1%) |
Mar 2018 | - | $335.49 M(-3.9%) |
Dec 2017 | $1.21 B(+9.0%) | $349.26 M(+21.1%) |
Sep 2017 | - | $288.39 M(-3.9%) |
Jun 2017 | - | $299.95 M(+9.5%) |
Mar 2017 | - | $273.95 M(-15.9%) |
Dec 2016 | $1.11 B(+9.0%) | $325.56 M(+12.6%) |
Sep 2016 | - | $289.24 M(+30.2%) |
Jun 2016 | - | $222.20 M(-19.1%) |
Mar 2016 | - | $274.54 M(+10.1%) |
Dec 2015 | $1.02 B(+29.5%) | $249.37 M(-2.5%) |
Sep 2015 | - | $255.87 M(-7.4%) |
Jun 2015 | - | $276.36 M(+16.2%) |
Mar 2015 | - | $237.78 M(-5.1%) |
Dec 2014 | $787.41 M(+28.0%) | $250.50 M(+23.4%) |
Sep 2014 | - | $202.93 M(+13.1%) |
Jun 2014 | - | $179.46 M(+15.6%) |
Mar 2014 | - | $155.19 M(-14.2%) |
Dec 2013 | $615.16 M(+18.5%) | $180.97 M(+13.4%) |
Sep 2013 | - | $159.54 M(+18.8%) |
Jun 2013 | - | $134.29 M(-4.3%) |
Mar 2013 | - | $140.35 M(-7.9%) |
Dec 2012 | $519.11 M(+32.7%) | $152.31 M(+33.6%) |
Sep 2012 | - | $113.99 M(-13.2%) |
Jun 2012 | - | $131.40 M(+8.2%) |
Mar 2012 | - | $121.41 M(+12.7%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2011 | $391.23 M(+28.1%) | $107.76 M(+1.2%) |
Sep 2011 | - | $106.50 M(+13.4%) |
Jun 2011 | - | $93.92 M(+9.1%) |
Mar 2011 | - | $86.05 M(-5.1%) |
Dec 2010 | $305.44 M(+26.0%) | $90.70 M(+16.7%) |
Sep 2010 | - | $77.71 M(+6.6%) |
Jun 2010 | - | $72.93 M(+12.6%) |
Mar 2010 | - | $64.75 M(+1.2%) |
Dec 2009 | $242.32 M(+18.7%) | $63.97 M(+14.8%) |
Sep 2009 | - | $55.70 M(-5.0%) |
Jun 2009 | - | $58.63 M(-8.4%) |
Mar 2009 | - | $64.02 M(+15.2%) |
Dec 2008 | $204.23 M(+27.2%) | $55.55 M(-1.2%) |
Sep 2008 | - | $56.23 M(+12.3%) |
Jun 2008 | - | $50.05 M(+18.1%) |
Mar 2008 | - | $42.39 M(-14.5%) |
Dec 2007 | $160.51 M(+60.3%) | $49.57 M(+31.0%) |
Sep 2007 | - | $37.85 M(-0.2%) |
Jun 2007 | - | $37.93 M(+6.8%) |
Mar 2007 | - | $35.51 M(+18.5%) |
Dec 2006 | $100.14 M(+14.8%) | $29.97 M(+13.4%) |
Sep 2006 | - | $26.43 M(+10.1%) |
Jun 2006 | - | $24.00 M(+21.5%) |
Mar 2006 | - | $19.75 M(-5.8%) |
Dec 2005 | $87.25 M(-46.3%) | $20.97 M(+1.9%) |
Sep 2005 | - | $20.59 M(-6.1%) |
Jun 2005 | - | $21.92 M(-7.8%) |
Mar 2005 | - | $23.77 M(-74.8%) |
Dec 2004 | $162.60 M(+85.0%) | $94.15 M(+251.7%) |
Sep 2004 | - | $26.77 M(+19.8%) |
Jun 2004 | - | $22.35 M(+15.6%) |
Mar 2004 | - | $19.34 M(-23.0%) |
Dec 2003 | $87.90 M(+30.0%) | $25.11 M(+21.5%) |
Sep 2003 | - | $20.67 M(-4.2%) |
Jun 2003 | - | $21.58 M(+5.0%) |
Mar 2003 | - | $20.54 M(+32.8%) |
Dec 2002 | $67.62 M(+42.0%) | $15.47 M(-16.9%) |
Sep 2002 | - | $18.61 M(+13.5%) |
Jun 2002 | - | $16.40 M(-4.4%) |
Mar 2002 | - | $17.14 M(+106.9%) |
Dec 2001 | $47.63 M(+4.9%) | $8.29 M(-36.9%) |
Sep 2001 | - | $13.14 M(+0.7%) |
Jun 2001 | - | $13.04 M(+17.2%) |
Mar 2001 | - | $11.13 M(+32.1%) |
Dec 2000 | $45.39 M(+46.0%) | $8.43 M(-34.0%) |
Sep 2000 | - | $12.77 M(+8.2%) |
Jun 2000 | - | $11.80 M(-4.8%) |
Mar 2000 | - | $12.39 M(+202.4%) |
Dec 1999 | $31.10 M(+110.1%) | $4.10 M(-65.0%) |
Sep 1999 | - | $11.70 M(+33.0%) |
Jun 1999 | - | $8.80 M(+33.9%) |
Mar 1999 | - | $6.57 M |
Dec 1998 | $14.80 M | - |
FAQ
- What is BioMarin Pharmaceutical annual total operating expenses?
- What is the all time high annual operating expenses for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual operating expenses year-on-year change?
- What is BioMarin Pharmaceutical quarterly total operating expenses?
- What is the all time high quarterly operating expenses for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly operating expenses year-on-year change?
What is BioMarin Pharmaceutical annual total operating expenses?
The current annual operating expenses of BMRN is $1.80 B
What is the all time high annual operating expenses for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual total operating expenses is $1.80 B
What is BioMarin Pharmaceutical annual operating expenses year-on-year change?
Over the past year, BMRN annual total operating expenses has changed by +$53.19 M (+3.05%)
What is BioMarin Pharmaceutical quarterly total operating expenses?
The current quarterly operating expenses of BMRN is $449.77 M
What is the all time high quarterly operating expenses for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly total operating expenses is $525.88 M
What is BioMarin Pharmaceutical quarterly operating expenses year-on-year change?
Over the past year, BMRN quarterly total operating expenses has changed by +$6.36 M (+1.43%)